Table 3 Site, surgeon, surgical and acute care characteristics.
Site & Surgeon | Description | Results N (%) or median (IQR) |
|---|---|---|
Sites | Public | 10 (54%) |
Private | 9 (46%) | |
Surgeons | 60 (30, 101) | |
Participants | Per surgeon | 60 (30.0, 101.0) |
Per site | 102.1 (49.3, 132.8) | |
Length of stay (days) | 5 (4.0, 7.0) | |
Surgical and acute care | ||
Joint (all surgeries) | Hip | 807 (43.9%) |
Knee | 1031 (56.1%) | |
Bilateral THA/TKA | Hip | 10 (0.5%) |
Knee | 80 (4.4%) | |
Surgical duration (hours) | (N = 1837) | 1.62 (1.2, 2.0) |
Processes of care | Neuraxial anaesthesia (N = 1836) | 1151 (62.7%) |
Routine doppler (N = 1810) | 343 (19.0%) | |
Cement fixation (N = 1837) | 1172 (63.8%) | |
Intra-articular drain (N = 1831) | 801 (43.7%) | |
Tourniquet (TKA) (N = 1032) | 885 (48.2%) | |
Blood transfusion (N = 1831) | 316 (17.3%) | |
Indwelling catheter | 1433 (78.1%) | |
VTE Prophylaxis | ||
Mechanical | Calf compressors (N = 1810) | 1410 (76.8%) |
Foot pumps (N = 1810) | 277 (15.0%) | |
Graduated compression stockings (GCS) (N = 1835) | 1399 (76.2%) | |
Used any SCD/GCS (N = 1835) | 1837 (98.6%) | |
Duration (days) | SCD and GCS (N = 1835) | 27 (15.0,38.0) |
Foot pumps only (N = 277) | 4 (3.0, 5.0) | |
Calf compressors only (N = 1410) | 3 (2.0, 4.0) | |
First mobilised day 0 or 1 | 1376 (75.0%) | |
Chemical | ||
Number of drugs | 0 | 7 (0.4%) |
1 | 1093 (59.5%) | |
2 | 678 (36.9%) | |
3 | 57 (3.1%) | |
4 | 2 (0.1%) | |
Duration of chemoprophylaxis | 22 (12,36) any duration | 30.5 (13,48) |
Preoperative use N (%) | ||
LMWH | 1439 (78.3%) | |
Enoxaparin sodium | 13 (0.7%) | 1047 (57.0%) |
Fragmin | 0 | 392 (21.3%) |
Aspirin (N = 1836) | 458 (24.9%) | 868 (47.3%) |
First dose 100–300 mg | Not reported | 847 (46.1%) |
Rivaroxaban | 13 (0.7%) | 160 (8.7%) |
Dabigatran etexilate | 9 (0.5%) | 11 (.6%) |
Apixaban | 2 (0.1%) | 10 (0.5%) |
Warfarin | 66 (3.6%) | 77 (4.2%) |
Unfractionated heparin | 4 (0.2%) | 73 (4.0%) |
Fondaparinux | 0 | 0 |
